Peer-influenced content. Sources you trust. No registration required. This is HCN.
Oncology News Central (ONC)
The FDA has approved a combination therapy of pembrolizumab, carboplatin, and paclitaxel for advanced endometrial cancer, significantly enhancing progression-free survival rates for patients with both mismatch repair deficient and proficient statuses.
Oncology, Medical July 2nd 2024
The New England Journal of Medicine
In a phase 3 trial, the combination of amivantamab and lazertinib resulted in a median progression-free survival of 23.7 months, surpassing the 16.6 months observed with osimertinib in patients with EGFR-mutated advanced NSCLC.
Oncology, Medical July 1st 2024
With nearly ten years of follow-up, dabrafenib plus trametinib demonstrates a sustained improvement in survival outcomes for patients with stage III BRAF V600–mutated melanoma, presenting a viable long-term strategy in melanoma management.
Dermatology July 1st 2024
A recent phase 3 trial demonstrates that a combination therapy of belantamab mafodotin, bortezomib, and dexamethasone leads to significantly longer progression-free survival in patients with relapsed or refractory multiple myeloma compared to a regimen including daratumumab.
Hematology/Oncology June 10th 2024
Recent trials in NSCLC treatment reveal that perioperative immunotherapy, including combinations like nivolumab and chemotherapy, can significantly improve disease-free survival in early-stage resectable NSCLC.
Oncology, Medical May 20th 2024
In the CheckMate 77T trial, perioperative nivolumab plus chemotherapy followed by adjuvant nivolumab significantly improved event-free survival and pathological responses in patients with resectable NSCLC. The safety profile was consistent with known data, reinforcing nivolumab’s potential as a cornerstone in perioperative lung cancer therapy.